John McCamant joined the Medical Technology Stock Letter as associate editor in 1987 and was named editor of this leading investment newsletter in August 2000.

Mr. McCamant has spent fourteen years on the frontlines of biotechnology investing.  As an equities analyst for the American Healthcare Fund, he uncovered investment opportunities and guided investment strategy.  At Burrill & Company, a San Francisco-based private merchant bank, he was a lead in raising a $75 million agbio venture capital fund.  Mr. McCamant is founder of Ten Peaks Capital, a financing company in the life sciences industry focused on business development and capital formation.  Mr. McCamant and Mr. Matthew Berry recently founded the Double Play Biotech Fund, a hedge fund focused on 'long' and 'short' investment plays in the biotechnology sector.

Mr. McCamant has established an extensive network that includes contacts throughout the investment banking and venture capital communities.  His expertise in biotechnology investments is a subject of media interest. He is frequently consulted and quoted by The Washington Post, Business Week, Reuter’s, Worth, and has been featured on CNN and CNBC.